Todd Foley, M.B.A.

Todd Foley is a Managing Director at MPM BioImpact and serves on a number of MPM portfolio company boards, including Aktis Oncology (Chairman), AstronauTx, Repare Therapeutics (NASDAQ: RPTX) and Tetherex Pharmaceuticals. Todd also serves as Chairman of portfolio companies ashibio and Crossbow Therapeutics. He previously served on the board of Semma Therapeutics, a potentially curative diabetes cell-therapy company founded by MPM and Doug Melton at Harvard, which was acquired by Vertex for $950M in 2019 in one of the largest ever preclinical M&A deals.  He guided Selexys Pharmaceuticals to an acquisition by Novartis for $665M in 2016. Later, Novartis launched the Selexys drug, Adakveo™ in late 2019 to treat sickle cell disease.

Prior to joining MPM in 1999, Todd’s career in the life science industry included business development at Genentech (Roche) and management consulting with Arthur D. Little.

Todd earned his M.B.A. from Harvard Business School and his B.S. in Chemistry from the Massachusetts Institute of Technology.